Companies: 10,795·Total market cap: $144.5T
Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc.

NEUPNASDAQHealthcare● Active
$4.67
+$0.18(+4.01%)
Market Cap$25239253
P/E Ratio
52W High$21.4
52W Low$3.645
SEC Filings

Neuphoria Therapeutics Inc. (NEUP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001191070 · NEUP · NASDAQ · as of Jun 9, 2026

Filing snapshot

410
Total Filings
8-K
Latest Form
2026-05-26
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001191070 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-09-29
Fiscal Year End
Sep 29, 2025
Accession No.
0001193125-25-223338
Primary Document
neup-20250630.htm
Source: data.sec.gov · CIK 0001191070 · Accession 0001193125-25-223338

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
8-KCurrent Report
CURRENT REPORT
2026-05-26Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
CURRENT REPORT
2026-05-26
View
10-QQuarterly Report
10-Q
2026-05-15
View
10-QQuarterly Report
10-Q
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-06
View
8-KCurrent Report
CURRENT REPORT
2026-01-08
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2025-12-29
View
8-KCurrent Report
CURRENT REPORT
2025-12-18
View
8-KCurrent Report
CURRENT REPORT
2025-12-17
View
DFAN14ADFAN14A
DFAN14A
2025-12-08
View
DFAN14ADFAN14A
DFAN14A
2025-12-08
View
DEFA14AProxy Statement (Additional)
DEFINITIVE ADDITIONAL MATERIALS
2025-12-08
View
DEFA14AProxy Statement (Additional)
DEFINITIVE ADDITIONAL MATERIALS
2025-12-04
View
DFAN14ADFAN14A
DFAN14A
2025-12-03
View
DFAN14ADFAN14A
DFAN14A
2025-12-02
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2025-12-02
View
Showing 1–15 of 398 filingsForm 4 / 144 hidden· 410 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001191070  |  Exchange: NASDAQ · Healthcare

Neuphoria Therapeutics Inc. (NASDAQ: NEUP) has submitted 410 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001191070, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Neuphoria Therapeutics Inc.'s most comprehensive regulatory disclosure. The most recent Neuphoria Therapeutics Inc. 10-K was filed on 2025-09-29 for fiscal year ending 2025. Historical NEUP 10-K annual reports are available from 2002 through 2025.

Investors researching Neuphoria Therapeutics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

NEUP SEC Filings · 8 questions

Neuphoria Therapeutics Inc. (NEUP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 410 filings and access original documents at no cost. Neuphoria Therapeutics Inc.'s CIK is 0001191070.

NEUP SEC filingsNeuphoria Therapeutics Inc. SEC documentsfind NEUP 10-K